Watson Pharmaceuticals Inc. (WPI) Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future “‘transformational’’ purchase as he reshapes the generic-drug maker. Bisaro, 51, said he wants to use an estimated $6 billion the company will have available for acquisitions to invest in brand-name medicines with the potential for greater growth and consistent returns. Watson will consider drugs for gender- specific conditions as it builds toward a ‘‘big brand deal.’’
